XTLB XTL Biopharmaceuticals Ltd.
Healthcare$2.38-5.18%ClosedMarket Cap: $5.6M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.82
P/S
13.87
EV/EBITDA
-6.48
DCF Value
$28.55
FCF Yield
-26.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.7%
Operating Margin
-481.6%
Net Margin
-227.7%
ROE
-26.8%
ROA
-12.0%
ROIC
-29.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 null | $289.0K | -14.9% | $-812.0K | $-255.0K | $— | — |
| FY null | $451.0K | 0.7% | $-2.2M | $-1.0M | $— | — |
| Q3 null | $162.0K | 100.0% | $-764.0K | $-553.0K | $— | — |
| Q2 null | $0.00 | NaN% | $-421.0K | $-704.0K | $— | — |
| Q1 null | $0.00 | NaN% | $-175.0K | $485.0K | $— | — |
| Q4 null | $0.00 | NaN% | $-200.0K | $-284.0K | $— | — |
| FY null | $0.00 | NaN% | $-765.0K | $-1.8K | $— | — |
| Q3 null | $0.00 | NaN% | $-151.0K | $-215.0K | $— | — |
| Q2 null | $0.00 | NaN% | $-163.0K | $-364.0K | $— | — |
| Q1 null | $0.00 | NaN% | $-251.0K | $-919.0K | $— | — |
| Q4 2022 | $0.00 | NaN% | $-225.0K | $-748.0K | $-2.24 | — |
| FY null | $0.00 | -Infinity% | $-880.0K | $-1.3M | $— | — |